Physician profile
Shruti Singh
NPI 1619210143
$155,986.15
in general payments reported to CMS, 2019-2025
75 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $1,418 · 2021: $7,143 · 2022: $25K · 2023: $61K · 2024: $43K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $64K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $11K · Travel and Lodging: $8,120 · Honoraria: $1,500 · Long Term Medical Supply Or Device Loan: $167 · Education: $94.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $64,398.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,972.00 |
| Food and Beverage | $10,539.90 |
| Travel and Lodging | $8,119.53 |
| Honoraria | $1,500.00 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $94.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39,934.57 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $33,546.29 | 2020-2025 | Enhertu, Andexxa, Calquence |
| Daiichi Sankyo INC. | $32,349.43 | 2020-2025 | Enhertu, Datroway |
| Amgen INC. | $10,378.22 | 2019-2023 | Kyprolis, Blincyto |
| Pharmacosmos Therapeutics INC. | $5,677.07 | 2022-2023 | Monoferric |
| Beigene USA, INC. | $4,420.57 | 2022-2024 | Brukinsa, Tevimbra |
| Fresenius Kabi USA, LLC | $4,085.35 | 2021-2024 | Stimufend |
| Karyopharm Therapeutics INC. | $2,388.34 | 2021-2023 | Xpovio |
| Janssen Biotech, INC. | $2,352.18 | 2020-2025 | Tecvayli, Talvey, Darzalex |
| Celgene Corporation | $1,941.08 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $1,895.11 | 2020-2024 | |
| Servier Pharmaceuticals LLC | $1,858.20 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,565.24 | 2020-2025 | |
| Seagen INC. | $1,436.88 | 2020-2023 | Tukysa, Padcev, Tivdak |
| Stemline Therapeutics INC. | $1,264.86 | 2024-2025 | Orserdu |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,147.83 | 2020-2025 | Perclose Prostyle, Diamondback Peripheral, Thoratec Heartmate 3 Lvas Implant Kit |
| Incyte Corporation | $1,097.17 | 2019-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $721.58 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $708.62 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Beigene, LTD. | $525.00 | 2021 | |
| Genentech USA, INC. | $497.04 | 2019-2025 | Tecentriq Hybreza, Venclexta, Polivy |
| Gilead Sciences, INC. | $401.28 | 2021-2025 | Trodelvy |
| Foundation Medicine, INC. | $396.02 | 2020-2023 | Foundationone Cdx |
| Abbvie INC. | $368.12 | 2020-2025 | Venclexta |
| Pfizer INC. | $337.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $333.17 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Sobi, INC | $293.28 | 2023-2024 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Genmab U.S., INC. | $269.28 | 2024-2025 | Epkinly |
| Exelixis INC. | $262.91 | 2020-2025 | Cabometyx |
| Ethicon INC. | $261.59 | 2021-2023 | Monarch Platform |
| Regeneron Healthcare Solutions, INC. | $238.76 | 2021-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $221.69 | 2020-2023 | Imbruvica |
| Puma Biotechnology, INC. | $206.88 | 2021-2022 | |
| Array Biopharma INC | $185.98 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Eisai INC. | $146.54 | 2019-2023 | |
| Sirtex Medical INC | $145.71 | 2022 | |
| Adc Therapeutics America, INC. | $141.51 | 2022 | |
| Clovis Oncology, INC. | $127.98 | 2020 | |
| Allergan, INC. | $126.71 | 2020 | |
| Intuitive Surgical, INC. | $125.53 | 2024 | |
| Alexion Pharmaceuticals, INC. | $117.23 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $116.03 | 2019-2024 | Jaypirca, Verzenio |
| Jazz Pharmaceuticals INC. | $87.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.70 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $66.09 | 2020-2022 | |
| Kite Pharma, INC. | $56.80 | 2020-2023 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $56.14 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.24 | 2024 | Ninlaro |
| Acrotech Biopharma INC. | $46.44 | 2021-2024 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $46.31 | 2020-2023 | |
| Amag Pharmaceuticals, INC. | $44.68 | 2019-2020 | |
| Epizyme, INC. | $43.12 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $40.12 | 2025 | |
| Tesaro, INC. | $36.17 | 2019 | |
| Syndax Pharmaceuticals, INC. | $33.56 | 2025 | |
| Fennec Pharmaceuticals, INC. | $33.36 | 2025 | Fyarro |
| Emd Serono, INC. | $33.03 | 2023-2024 | Tepmetko |
| Pharmaessentia USA Corporation | $28.79 | 2022 | |
| Myovant Sciences INC. | $28.53 | 2022 | |
| Advanced Accelerator Applications | $26.21 | 2019-2020 | |
| Immunomedics, INC. | $26.05 | 2020 | |
| Spectrum Pharmaceuticals INC. | $24.74 | 2024 | Rolvedon |
| Blueprint Medicines Corporation | $23.94 | 2024 | Ayvakit |
| Sumitomo Pharma America, INC. | $22.86 | 2024 | Orgovyx |
| Tolmar, INC. | $22.64 | 2023 | |
| Deciphera Pharmaceuticals INC. | $21.74 | 2024 | Qinlock |
| Tersera Therapeutics LLC | $19.45 | 2024 | Zoladex |
| Janssen Pharmaceuticals, INC | $18.71 | 2020 | |
| Verity Pharmaceuticals INC. | $18.25 | 2023 | Trelstar |
| Agios Pharmaceuticals, INC. | $16.96 | 2023 | Pyrukynd |
| Morphosys, US INC. | $16.95 | 2023 | Monjuvi |
| Mirati Therapeutics, INC. | $13.89 | 2024 | Krazati |
| Taiho Oncology, INC. | $12.07 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.